The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
Why Sustainable Biomanufacturing Must Start Earlier in The Process
Clinically Validated Probiotics
From Snapshots to Movies
Beyond Reporting - Safety surveillance analytics for medical devices...
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Life Sciences - Clinical, TNT Asia
Director
Clinical trials have very detailed and precise processes and the logistical elements of these processes are critical Recent revisions to the pharmaceutical industrys regulatory laws as well as improved patent laws in countries such as Japan China and India have led to the burgeoning clinical trials market in Asia
Articles
Harnessing Plant Potential
Biotechnology has achieved remarkable milestones with plantbased production of biotherapeutics emerging as a compelling innovation Traditionally biotherapeutics have been manufactured through microbial fermentation or animal cell cultivation but plants offer a greener more costeffective alternative Thanks to advances in genetic engineering and biological processing
Research Insights
Biosensor-based engineering of biosynthetic pathways
Biosynthetic pathways provide an enzymatic route from inexpensive renewable resources to valuable metabolic products such as pharmaceuticals and plastics Designing these pathways is challenging due to the complexities of biology Advances in the design and construction of genetic variants has enabled billions of cells each possessing a slightly different metabolic design to be rapidly generated However our abi
Case Studies
Pediatrician’s Cough And Cold Medication Prescription For Hypothetical Cases: A Cross-Sectional Multi-Centric Case Study
Abstract Cough and cold is the most common cause for hospital visits and so is the use of cough and cold medication CCM A cough and cold medication has been considered to contain a single ingredient SI or multiple ingredients MI like promethazine PRZ chlorpheniramine CPM pseudoephedrine PS phenylephrine PE diphenhydramine DPH dextromethor
Techno Trends
Portola Pharmaceuticals Introduces Antidote for the Reversal of Factor Xa Inhibitors
Portola Pharmaceuticals develops Andexxa coagulation factor Xa recombinant inactivatedzhzo the first and only antidote indicated for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to lifethreatening or uncontrolled bleeding Andexxas rapid reversal of the anticoagulating effects of rivaroxaban and apixaban will help cli...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Accelerating the Medical Writing Process with Automation From research to publication
Nirupama Parate a Senior Associate at Freyr Solutions’ Medicinal Products Division is an MBA Pharmaceutical Tech graduate and has a knack for Medical Writing Automation. She holds experience across pharmaceutical and medical devices ranging from Regulatory Affairs, pharmaceutical marketing and communications, and medical writing automation. She strongly believes in walking the extra mile and adding a personal touch to everything she does.
Tiny Vesicles, Big Impact
Dr. Disha Marwaha received her PhD in biological sciences from CSIR-Central Drug Research Institute (CSIR-CDRI), India in 2024. She is currently an Assistant Professor at the GLA University, Mathura. She has more than 20 publications in international peer-reviewed Journals. She is an expert in formulation and development, nanomedicine and pharmacokinetics focusing on innovative therapeutic and targeted drug delivery systems.
Dr. Neha Singh received her Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI), India, in 2025. She is currently an Assistant Professor at the Lloyd School of Pharmacy, Greater Noida. Dr. Singh has contributed extensively to the field of pharmaceutical sciences, with many publications, patents, and book chapters in internationally recognised peer-reviewed journals. Her primary research interests include formulation development, nanomedicine and pharmacokinetics, with a focus on innovative therapeutic strategies and targeted drug delivery systems. Dr. Singh’s work reflects her commitment to advancing precision medicine and developing next-generation solutions for healthcare.
Innovative Tool For Drug Design And Development
S.Subash awarded 2 best poster presentation awards and secured 1st place in Poster presentation. I published three articles in national and international peer reviewed journal. And, also attend many conferences to upgrade knowledge.
Therapeutic Peptides
Rienzi Mosqueda is a dedicated writer specialising in life science, health, and pharma content. With a passion for clear, engaging writing, Rienzi provides fresh perspectives on each topic. His ability to simplify complex ideas makes the articles valuable for readers of all backgrounds. As an emerging voice, Rienzi Mosqueda is committed to sharing knowledge and sparking discussions through their impactful writing.
The Transformative Impact of AI on Regulatory Affairs
Yu Han, DPhil in Engineering Science from the University of Oxford, brings a rich background with experience at manufacturer, global regulatory affairs CRO, and AI sector. Her expertise spans the regulatory landscapes of Asia, the US, and the EU, providing a comprehensive understanding of global pharmaceutical regulations. Passionate about combining AI technology with healthcare, Yu excels in creating innovative engineering tools to advance medical solutions. Her work leverages engineering methodologies to unravel complexities in the medical listing process, streamlining the global product flow.
<p> </p>
Email: yu.han@eng.ox.ac.uk
press releasesRead more...
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Telix and Ekalia a joint venture between IBA Ion Beam Applications SA EURONEXT and Framatome today announced a collaboration to advance scalable United States US production of astatine At an alphaemitting radioisotope being investigated for targeted alpha therapy
HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases
HistoIndex a pioneer in AIdriven digital pathology for fibrotic diseases and the Agency for Science Technology and Research ASTAR Singapores lead public sector RD agency have signed a Memorandum of Understanding MoU to collaborate on the preclinical evaluation
Cotecna Group Acquires Energon Labs
Cotecna a leading provider of Testing Inspection and Certification TIC services today announced the acquisition of Energon Labs a cGMPcompliant USFDAinspected ISO and ISO certified analytical testing laboratory based in Hyderabad India
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
EventsRead more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWSRead more...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...
